X

Trial Profile

An Expanded Access Protocol for Mobocertinib in Refractory Non-Small Cell Lung Cancer Patients With EGFR exon20 Insertion Mutations

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Oct 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mobocertinib (Primary)
Indications Non-small cell lung cancer
Focus Expanded access; Therapeutic Use
Sponsors Takeda Oncology

Most Recent Events

13 Sep 2022 Results reporting real-world treatment duration using patients data from this EAP trial presented at the 47th European Society for Medical Oncology Congress
20 Sep 2021 Status changed from recruiting to completed.
04 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com